Do CLL patients with mutated immunoglobulin receptors respond better to therapy?

Paolo Ghia

Paolo Ghia, MD, PhD from the San Raffaele Hospital, Milan, Italy, gives us an insight into the possible association of chronic lymphocytic leukemia (CLL) patients who have mutated immunoglobulin receptors and their good response to chemoimmunotherapy (i.e. longer progression-free and overall survival), compared to those without mutations. He mentions a study that is currently being conducted to investigate this phenomenon. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

Share this video